{"filing":{"accession_number":"0001193125-26-282990","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d167360d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000119312526282990/d167360d8k.htm"},"events":[{"id":13985,"run_id":12436,"accession_number":"0001193125-26-282990","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Ligand completed a $700 million issuance of 0.00% convertible senior notes due 2031 on June 25, 2026, in a private placement to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The offering included convertible note hedge transactions and warrant transactions, with net proceeds of $678.2 million designated for general corporate purposes and share repurchases.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11287,"accession_number":"0001193125-26-282990","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Ligand completed a $700 million issuance of 0.00% convertible senior notes due 2031 on June 25, 2026, pursuant to an indenture with U.S. Bank Trust Company. This is a material creation of a direct financial obligation. While the notes are convertible into common stock, the primary event disclosed is the debt issuance itself, not equity dilution, making debt_issuance the most appropriate classification over dilutive_issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11288,"accession_number":"0001193125-26-282990","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Ligand issued $700 million aggregate principal amount of 0.00% convertible senior notes due 2031 in a private placement, closing on June 25, 2026. This represents the creation of a direct financial obligation under Item 2.03. The filing explicitly references Item 1.01 (which typically covers M\u0026A but here covers the debt offering details), and the exhibits detail the pricing, terms, conversion features, and use of proceeds for this material debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11290,"accession_number":"0001193125-26-282990","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Ligand issued $700 million aggregate principal amount of 0.00% convertible senior notes due 2031 in a private placement to qualified institutional buyers. The filing discloses the pricing on June 22, 2026 and closing on June 25, 2026 of this debt offering, along with details on use of proceeds ($678.2 million net), convertible note hedge transactions, warrant transactions, and concurrent share repurchases. This is a material creation of a direct financial obligation and represents a significant capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13986,"run_id":12436,"accession_number":"0001193125-26-282990","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"In connection with the convertible notes offering, Ligand issued warrants to purchase up to approximately 4.19 million shares of common stock, and the convertible notes may result in the issuance of up to 2.67 million shares upon conversion, representing a material dilutive capital raise through unregistered securities.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11289,"accession_number":"0001193125-26-282990","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of $625–700 million in convertible senior notes and warrants to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The filing explicitly states the Notes and Warrants \"have not been registered under the Securities Act\" and describes the exemptions relied upon. The press release confirms this is a private placement raising capital through dilutive securities: up to 2.67 million shares may be issued upon conversion of the Notes, and approximately 4.19 million shares upon exercise of the Warrants. This is a classic dilutive capital raise by a mid-cap pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11287,"accession_number":"0001193125-26-282990","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Ligand completed a $700 million issuance of 0.00% convertible senior notes due 2031 on June 25, 2026, pursuant to an indenture with U.S. Bank Trust Company. This is a material creation of a direct financial obligation. While the notes are convertible into common stock, the primary event disclosed is the debt issuance itself, not equity dilution, making debt_issuance the most appropriate classification over dilutive_issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25"},{"id":11288,"accession_number":"0001193125-26-282990","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Ligand issued $700 million aggregate principal amount of 0.00% convertible senior notes due 2031 in a private placement, closing on June 25, 2026. This represents the creation of a direct financial obligation under Item 2.03. The filing explicitly references Item 1.01 (which typically covers M\u0026A but here covers the debt offering details), and the exhibits detail the pricing, terms, conversion features, and use of proceeds for this material debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25"},{"id":11289,"accession_number":"0001193125-26-282990","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of $625–700 million in convertible senior notes and warrants to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The filing explicitly states the Notes and Warrants \"have not been registered under the Securities Act\" and describes the exemptions relied upon. The press release confirms this is a private placement raising capital through dilutive securities: up to 2.67 million shares may be issued upon conversion of the Notes, and approximately 4.19 million shares upon exercise of the Warrants. This is a classic dilutive capital raise by a mid-cap pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25"},{"id":11290,"accession_number":"0001193125-26-282990","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Ligand issued $700 million aggregate principal amount of 0.00% convertible senior notes due 2031 in a private placement to qualified institutional buyers. The filing discloses the pricing on June 22, 2026 and closing on June 25, 2026 of this debt offering, along with details on use of proceeds ($678.2 million net), convertible note hedge transactions, warrant transactions, and concurrent share repurchases. This is a material creation of a direct financial obligation and represents a significant capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:04.123564+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-25"}]}